Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.
about
Structure activity relationship of phenolic acid inhibitors of α-synuclein fibril formation and toxicity2-Amino-1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) is selectively toxic to primary dopaminergic neurons in vitroSubacute manganese exposure in rats is a neurochemical model of early manganese toxicityA strategy for the generation, characterization and distribution of animal models by The Michael J. Fox Foundation for Parkinson's ResearchBehavioral, neurochemical, and pathologic alterations in bacterial artificial chromosome transgenic G2019S leucine-rich repeated kinase 2 rats.A rapid and sensitive automated image-based approach for in vitro and in vivo characterization of cell morphology and quantification of cell number and neurite architecture.mTOR Signaling in Parkinson's Disease.Corynoxine, a natural autophagy enhancer, promotes the clearance of alpha-synuclein via Akt/mTOR pathway.From the Cover: Alterations in Optineurin Expression and Localization in Pre-clinical Parkinson's Disease ModelsE46K α-synuclein pathological mutation causes cell-autonomous toxicity without altering protein turnover or aggregation.Individual Amino Acid Supplementation Can Improve Energy Metabolism and Decrease ROS Production in Neuronal Cells Overexpressing Alpha-Synuclein.New developments in genetic rat models of Parkinson's disease.Synthetic alpha-synuclein fibrils cause mitochondrial impairment and selective dopamine neurodegeneration in part via iNOS-mediated nitric oxide production.Cellular and Molecular Basis of Neurodegeneration in Parkinson Disease.NCX1 and NCX3 as potential factors contributing to neurodegeneration and neuroinflammation in the A53T transgenic mouse model of Parkinson's Disease.
P2860
Q34003885-3092B45E-F7AC-49BE-AD0E-7217818B87A0Q34048236-471CE203-F752-4356-ABE3-A08AEB7E638AQ34781459-0C19B2D2-71D3-45C4-AA2C-6B8CD9C3472BQ37287403-FF122951-66C2-462D-8EB2-E6BF9C7411E5Q37621247-D73B98F0-E00B-403E-A9C7-38BB562D7988Q38201363-2D9E3AAF-756B-4B8E-9A2B-E0D7C0E823FEQ38855225-F6060833-CB77-4A09-9857-8CB0A7255618Q39024437-33F65F1D-CEA9-40EA-B55E-80512161AA5EQ41658088-3CC82D7F-D5D8-422C-9671-07DF5F9556C0Q46308077-FB73D4ED-4C21-451C-BD46-2DDFD82BF9B5Q46349223-E69B25B3-3BA9-4A9F-A8DF-CF5F3BC5B278Q48502440-FDEE6570-0D06-40B0-BFCD-875D596F1C02Q50630062-D4C8F613-54C1-4511-B6EF-E83110A07E22Q55048859-D4633D92-F699-42FF-9E67-94B3E043117BQ55512119-E7E984CE-9A51-424D-88E7-5BA6DA8D316F
P2860
Expression of human E46K-mutated α-synuclein in BAC-transgenic rats replicates early-stage Parkinson's disease features and enhances vulnerability to mitochondrial impairment.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
Expression of human E46K-mutat ...... y to mitochondrial impairment.
@ast
Expression of human E46K-mutat ...... y to mitochondrial impairment.
@en
type
label
Expression of human E46K-mutat ...... y to mitochondrial impairment.
@ast
Expression of human E46K-mutat ...... y to mitochondrial impairment.
@en
prefLabel
Expression of human E46K-mutat ...... y to mitochondrial impairment.
@ast
Expression of human E46K-mutat ...... y to mitochondrial impairment.
@en
P2093
P2860
P50
P1476
Expression of human E46K-mutat ...... ty to mitochondrial impairment
@en
P2093
Chenjian Li
Kindiya D Geghman
Michelle K Dail
Thomas Sew
P2860
P356
10.1016/J.EXPNEUROL.2012.11.007
P407
P577
2012-11-12T00:00:00Z